Why Rhythm Pharmaceuticals, Inc. (RYTM) stock rose 28.0% on Wednesday, November 4, 2026

Rhythm Pharmaceuticals, Inc. (RYTM) closed at $110.68, up 28.04% on Wednesday, November 4, 2026, on volume of 4,956,179 shares (6.5× its 3-month average); market value about $7.70B.

What happened: primary sources

Events Nexqual found for RYTM on Wednesday, November 4, 2026 or the trading day before (November 3, 2026):

• Nov 3, 2026: Reported Q3 2026 results: EPS −$0.61 vs consensus −$0.74 (beat), revenue $92.1M vs consensus $84.6M (beat). Guidance: Rhythm anticipates approximately $360 million to $380 million in Non-GAAP Operating Expenses for the year ending December 31, 2026. source
• Nov 4, 2026: Citizens: Target raised, Market Outperform, price target $160 → $166
• Nov 3, 2026: Needham: Target lowered, Buy, price target $130 → $114

These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.

More on RYTM

RYTM stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Earnings report: RYTM results, November 3, 2026. Other big moves that day: November 4, 2026.

Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 10, 2026 at 16:45 UTC. Not investment advice.

Data source: Nexqual. Last updated: November 10, 2026 at 16:45 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt